Shedding light on developmental drugs for idiopathic pulmonary fibrosis.

Expert Opinion on Investigational Drugs
P SpagnoloT M Maher

Abstract

Idiopathic pulmonary fibrosis (IPF) is an age-related disease of unknown cause. The disease is characterized by relentless scarring of the lung parenchyma resulting in respiratory failure and death. Two antifibrotic drugs (pirfenidone and nintedanib) are approved for the treatment of IPF worldwide, but they do not offer a cure and are associated with tolerability issues. Owing to its high unmet medical need, IPF is an area of dynamic research activity. There is a growing portfolio of novel therapies that target different pathways involved in the complex pathogenesis of IPF. In this review, we discuss the mechanisms of action and available data for compounds in the most advanced stages of clinical development. We searched PubMed for articles on this topic published from 1 January 2000, to 6 June 2020. The approval of pirfenidone and nintedanib has fueled IPF drug discovery and development. New drugs are likely to reach the clinic in the near future. However, numerous challenges remain; the lack of animal models that reproduce the complexity of human disease and the poor translation of preclinical and early-phase positive effects to late stage clinical trials must be tackled.

References

May 1, 1998·American Journal of Respiratory and Critical Care Medicine·A L Katzenstein, J L Myers
May 12, 2004·American Journal of Physiology. Lung Cellular and Molecular Physiology·Tina L Sumpter, David S Wilkes
Aug 23, 2006·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Edwin Roger ParraVera Luiza Capelozzi
Jan 30, 2007·Allergology International : Official Journal of the Japanese Society of Allergology·Yumiko NishiKoji Shirai
Sep 6, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Darrell PillingRichard H Gomer
Oct 6, 2007·American Journal of Respiratory and Critical Care Medicine·Khalid PuthawalaJohn S Munger
Feb 20, 2008·Current Opinion in Cell Biology·Michael F Olson
Mar 13, 2008·Journal of Cell Science·John F AlcornYvonne M W Janssen-Heininger
Oct 7, 2008·American Journal of Respiratory Cell and Molecular Biology·John F AlcornYvonne M W Janssen-Heininger
Oct 22, 2008·Oncogene·D N Dhanasekaran, E P Reddy
Jul 15, 2009·Immunological Reviews·Neil C Henderson, Tariq Sethi
Jan 9, 2010·Annual Review of Pharmacology and Toxicology·Ji Woong ChoiJerold Chun
Apr 7, 2010·Science Translational Medicine·Ana P CastañoJeremy S Duffield
Oct 12, 2010·American Journal of Respiratory and Critical Care Medicine·Brett LeyTalmadge E King
Mar 11, 2011·The New England Journal of Medicine·George R WashkoUNKNOWN COPDGene Investigators
Aug 26, 2011·Clinica Chimica Acta; International Journal of Clinical Chemistry·Masato KonoKingo Chida
Nov 19, 2011·American Journal of Respiratory and Critical Care Medicine·Alison C MackinnonTariq Sethi
Jun 30, 2012·American Journal of Respiratory Cell and Molecular Biology·Nikos OikonomouVassilis Aidinis
Sep 12, 2012·Nature Reviews. Genetics·Mary Armanios, Elizabeth H Blackburn
Feb 26, 2013·The Journal of Clinical Investigation·Yong ZhouVictor J Thannickal
Apr 12, 2013·Journal of Inflammation Research·Nevins W ToddSergei P Atamas
May 23, 2013·The New England Journal of Medicine·Gary M HunninghakeDavid A Schwartz
Sep 21, 2013·Annual Review of Pathology·Paul J WoltersKirk D Jones
Nov 30, 2013·Respirology : Official Journal of the Asian Pacific Society of Respirology·Gregory J KeirElisabetta A Renzoni
Mar 20, 2014·American Journal of Respiratory and Critical Care Medicine·Moisés Selman, Annie Pardo
May 20, 2014·The New England Journal of Medicine·Luca RicheldiUNKNOWN INPULSIS Trial Investigators
May 20, 2014·The New England Journal of Medicine·Talmadge E KingUNKNOWN ASCEND Study Group
Dec 3, 2014·Journal of Autoimmunity·Antoine FrançoisIsabelle Couillin
Dec 17, 2014·The European Respiratory Journal·Takashi OguraYukihiko Sugiyama
Jan 24, 2015·Annals of Medicine·Paolo SpagnoloCarlo Vancheri
Jan 24, 2015·The European Respiratory Journal·David S WilkesKatia Rothhaar
Apr 23, 2015·The European Respiratory Journal·Harold R CollardKevin K Brown
May 13, 2015·The Journal of Experimental Medicine·Andrea DoniAlberto Mantovani
May 16, 2015·The European Respiratory Journal·John HutchinsonTricia McKeever

❮ Previous
Next ❯

Citations

Feb 9, 2021·Current Opinion in Pharmacology·Katerina M AntoniouDemosthenes Bouros

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Expert Opinion on Pharmacotherapy
Francesco VaroneL Richeldi
© 2022 Meta ULC. All rights reserved